Skip to content

Evaluating the Analgesic Effect of Bupivacaine Liposome at Different Volumes (Equivalent Dose) for Local Infiltration Analgesia Following Total Knee Arthroplasty: A Single-Center, Randomized, Multi-Arm Study

Analgesic Efficacy of Fixed-Dose Liposomal Bupivacaine at Different Volumes for Local Infiltration After Total Knee Arthroplasty: Single-Center, Randomized, Multi-Arm Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115727
Enrollment
Unknown
Registered
2025-12-30
Start date
2025-11-03
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain After Total Knee Arthroplasty

Interventions

Intervention Group 1:Liposomal Bupivacaine 266 mg/40 ml (total volume)
Intervention Group 3:Liposomal Bupivacaine 266 mg/60 ml (total volume)
Intervention Group 2:Liposomal Bupivacaine 266 mg/60 ml (total volume)

Sponsors

Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily signs the informed consent form; 2. Scheduled to undergo unilateral total knee arthroplasty (TKA) under general anesthesia for primary knee osteoarthritis; 3. Aged >=18 years, regardless of gender; 4. American Society of Anesthesiologists (ASA) physical status classification of I to III.

Exclusion criteria

Exclusion criteria: 1. Comorbid psychiatric disorders (e.g., schizophrenia, depression) or sensory disorders (e.g., hyperalgesia); 2. Presence of other severe underlying diseases (e.g., cardiovascular or cerebrovascular diseases) during the screening period that, in the investigator's judgment, render the patient unsuitable to tolerate the surgery; 3. Known allergy, hypersensitivity, or contraindication to bupivacaine, ropivacaine, other amide-type local anesthetics, or any other drugs that may be used during the trial, such as propofol, remimazolam, opioids, dexamethasone, etc. 4. History of drug abuse, illicit drug use, and/or alcohol abuse within 1 year prior to randomization; 5. Female subjects who are pregnant or lactating; 6. Participation in any other clinical trial as a subject within 3 months prior to randomization and/or previous participation in a clinical trial involving the investigational drug or device of this study; 7. Patients with rheumatoid arthritis; 8. Body Mass Index (BMI) >35 kg/m²; 9. Subjects whom the investigator considers to have any other factors that make them unsuitable for participation in this trial.

Design outcomes

Primary

MeasureTime frame
Postoperative pain intensity assessed using the Visual Analog Scale (VAS) during activity;

Secondary

MeasureTime frame
Postoperative Sleep Quality Scale (Athens Insomnia Scale);Postoperative pain intensity assessed using the Visual Analog Scale (VAS) at rest.;

Countries

China

Contacts

Public ContactZhihong Xu

Drum Tower Hospital

xuzhihongjoint@hotmail.com+86 13912988032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026